Heart-failure from retention of salt and water caused by treatment with pentapyrrolidinium bitartrate.
作者信息
RØNNOV-JESSEN V
出版信息
Lancet. 1955 Jan 15;268(6855):122-4. doi: 10.1016/s0140-6736(55)91699-8.
Abstract
摘要
相似文献
1
Heart-failure from retention of salt and water caused by treatment with pentapyrrolidinium bitartrate.
Lancet. 1955 Jan 15;268(6855):122-4. doi: 10.1016/s0140-6736(55)91699-8.
2
Fluid retention during methonium therapy.美索铵治疗期间的液体潴留。
Australas Ann Med. 1954 Aug;3(3):234-7. doi: 10.1111/imj.1954.3.3.234.
3
Congestive heart failure in rheumatic heart disease; toxic action of salt.风湿性心脏病中的充血性心力衰竭；盐的毒性作用。
Trans Am Coll Cardiol. 1956 Jun;6(1):102-9.
4
A case of intestinal obstruction following the administration of pentapyrrolidinium bitartrate (ansolysen).
Med J Aust. 1957 Dec 14;44(24):860-1. doi: 10.5694/j.1326-5377.1957.tb60423.x.
5
[Treatment of arterial hypertension with M & B 2050A (pentapyrrolidinium bitartrate)].用M&B 2050A（酒石酸戊吡咯铵）治疗动脉高血压
Arch Hosp Univ. 1955 Mar-Apr;7(2):113-9.
6
[Drug therapy of arterial hypertension; pentapyrrolidinium bitartrate (ansolysen), a new remedy for peroral use].[动脉高血压的药物治疗；酒石酸戊哌啶铵（安索利森），一种新的口服药物]
Ugeskr Laeger. 1954 Apr 15;116(15):551-8.
7
CARDIAC clinic.心脏病诊所
Heart Bull. 1955 Sep-Oct;4(5):87.
8
Pentapyrrolidinium bitartrate (M. & B. 2050A) in the treatment of hypertension; preliminary observations.酒石酸戊哌啶铵（M. & B. 2050A）治疗高血压的初步观察
Proc Staff Meet Mayo Clin. 1954 Sep 1;29(18):496-508.
9
Permanent bilateral blindness following the use of hexamethonium chloride.使用氯化六甲双铵后出现永久性双侧失明。
AMA Arch Ophthalmol. 1955 Sep;54(3):422-4.
引用本文的文献
1
Cardiac failure with reserpine.利血平所致心力衰竭
Br Med J. 1956 Feb 4;1(4961):267-9. doi: 10.1136/bmj.1.4961.267.
Zotero 插件